Alamar Biosciences Inc. is wrongly utilizing protected molecular-analysis technology in its new biomarker detection and quantification system without permission from the Swedish company that invented the process, according to a new lawsuit.
Olink Proteomics AB said Alamar’s NULISA platform infringes US Patent No. 7,883,848, which covers proprietary testing processes for producing unique DNA sequences that are “a valuable tool for quantitative protein analysis,” according to a complaint filed in the US District Court for the District of Delaware.
The ‘848 patent—issued in 2011—is “generally directed to methods of detecting functional interactions between at least two molecules of interest,” according ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.